Laddar populära aktier...
Q3 slightly slower than expected, partly due to discontinued product We cut '24e-'26e adj.
Redeye keeps its Base Case despite cutting its 2024-2025 EBIT forecasts following a Q3 report with somewhat soft numbers.
Redeye sees a stable Q3 from Formpipe, with sales and adjusted EBIT roughly matching our expectations.
- Q2 sales impacted by lower Public DK deliveries – again - We cut '24e-'26e EBIT by 12-5% on lower sales assumptions - Slowdown in margin p...
Redeye reduces its Base Case slightly despite cutting its 2024-2025 EBIT forecasts following a mixed Q2 report.
Redeye sees an overall solid report, with the rebound in ACV being the highlight.
Softer Q1 than expected, but with solid progress for Private We cut '24e-'26e EBIT by 22-6% on lower sales and higher opex Slowdown in margi...
Redeye reduces its Base Case slightly despite cutting its 2024-2025 EBIT forecasts following a soft Q1 report.
Redeye sees a softer Q1 report than expected. Sales, EBIT, and the forward-looking ACV were softer than expected.
Redeye retains its Base Case despite cutting its short-term EBIT forecasts slightly.
Good ending to 2023 with strong margin improvements We lift '24e-'25e EBIT by 9-5% on lower opex Share is trading at 23x and 15x '24e and '2...
Redeye retains its positive view of Formpipe following a Q4 report largely matching our expectations.
Sales +7% y-o-y, +1% vs. ABGSCe 12.7% adj. EBIT margin (vs.
Redeye retains its positive view of Formpipe following a Q4 matching our forecasts.
Early Signs of Improved Momentum in Private.
Solid Q3 report – margins continue to improve We make small revisions to '24e-'25e EBIT Share is trading at 23x-15x '24e-'25e EV/EBIT 6% sa...
Sales +5% y-o-y, -6% vs. ABGSCe on lower delivery sales 11% adj.
Redeye sees a Q3 report with solid ACV numbers, but with sales and EBIT hurt by lower Deliveries in Public DK than we expected.
• Better-than-expected Q2 report, mainly driven by Public DK • We raise our EBIT estimates on lower costs • We continue to see improved marg...
Redeye retains its positive view of Formpipe following a Q2 report largely matching our expectations.
Redeye retains its positive view of Formpipe following a solid Q2, largely matching our forecasts.
Q2 report due on Friday 14 July Estimates fine-tuned Q2e EBIT margin of 6.
Magnus Svenningson will take the helm on 1 Aug Software experience: both from public and private sector We expect focus to remain on Private...
3% sales miss, but better underlying profits than expected '23e-'25e EBIT down 12-5% on lower sales and higher D&A Key peer for Private (Sig...
Redeye retains its positive view of Formpipe following a solid Q1 report with robust ACV and early signs of the expected margin increases.
Sales +6% y-o-y, -3% vs. ABGSCe 6% EBIT margin (3% in Q1'22), supported by slowdown in opex Cons.
Redeye will likely keep its Base Case and forecasts largely unchanged following a solid Q1 report with ACV in line with expectations.
Temenos' SaaS sales grew 32% in 2022 Earlier this week, Formpipe's banking platform partner, Temenos, reported its Q4 numbers and hosted a c...
Another quarter with poor margins... ...but recent slowdown in opex bodes well for '23e margins 21x '24e EV/EBIT, '21-'25e sales CAGR of 11%...
Redeye strengthens its positive view of Formpipe following the solid Q4 report showing a record-high ACV.
Redeye retains its positive view of Formpipe following robust preliminary Q4 figures.
Preliminary Q4 sales in line with ABGSCe, EBIT slightly above CEO Christian Sundin leaves after 16 years at helm Expect modest revisions for...
Redeye retains its positive view of Formpipe despite lowering its forecasts and Base Case.
Poor Q3 margins on lower delivery sales in Public DK We cut ‘22e-‘24e EBIT by 13-8% Opex growth to slow down & margins to improve in ‘23e T...
Sales +10% y-o-y, but -2% vs. ABGSCe Margin suffering from Public DK reporting sales -8% y-o-y Expect cons.
Redeye believes Formpipe’s Q3 was on the softer side due to the lower-than-expected ACV, following postponed investments in the banking sect...
Q3 report due on Thursday, 27 October Negative EBIT revisions on more cautious sales ests.
Redeye retains its positive view on Formpipe following a solid Q2 report with strong ACV and positive signs in Public SE.
4% sales miss, mainly due to lower license sales We cut our EBIT estimates on higher costs We continue to see strong growth prospects Better...
Sales 17% y-o-y but -4% vs. ABGSCe Expect negative estimate revisions on higher costs Share is trading at 21x ‘23e EV/EBIT on unrevised ests...
Redeye retains its positive view of Formpipe. While the headline numbers look weak at first glance, ACV was strong, and the initiatives in P...
Redeye retains its positive view of Formpipe following its deliveries deal with Malmö Stad.
Redeye retains its positive view on Formpipe despite forecasting zero margins in 2022.
Sales up 19% y-o-y, solid growth in all three segments Sales estimates up slightly, but we reduce ‘22e EBIT Share is trading at 20x EV/EBIT ...
Redeye will likely raise its short-term cost forecasts slightly while leaving long-term margin assumptions largely unchanged, following a Q1...
Sales +19% y-o-y, +1% vs. ABGSCe… …but a weaker margin than expected due to higher costs Expect cons.
Redeye retains its positive view on Formpipe despite increasing our cost forecasts for 2022E and 2023E.
Redeye retains its positive view on Formpipe following a Q4 report with solid ARR growth.
Redeye’s preliminary revisions suggest largely unchanged forecasts for 2022E and 2023E, as the strong momentum seen in Q2 and Q3 remained in...
Redeye sees a solid Q4 report from Formpipe where ARR growth remains solid, partly thanks to strong new sales in Public DK.
Redeye reinforces its positive view on Formpipe following a strong Q2 report with record-high ARR growth.
Adj. sales up 2% y-o-y but -4% vs. ABGSCe There were two key areas worth emphasising in FormPipe’s Q2 report.
Redeye reinforces its upbeat view on Formpipe following a solid report with record-high ARR growth.
Q2 results – positive non-recurring item of SEK 25.
